Open Access

MicroRNA-6826 and -6875 in plasma are valuable non‑invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer

  • Authors:
    • Taiki Kijima
    • Shoichi Hazama
    • Ryouichi Tsunedomi
    • Hironori Tanaka
    • Hiroko Takenouchi
    • Shinsuke Kanekiyo
    • Yuka Inoue
    • Masao Nakashima
    • Michihisa Iida
    • Kazuhiko Sakamoto
    • Nobuaki Suzuki
    • Shigeru Takeda
    • Tomio Ueno
    • Shigeru Yamamoto
    • Shigefumi Yoshino
    • Kiyotaka Okuno
    • Hiroaki Nagano
  • View Affiliations

  • Published online on: November 22, 2016     https://doi.org/10.3892/or.2016.5267
  • Pages: 23-30
  • Copyright: © Kijima et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Various vaccine treatments against metastatic colorectal cancer have been developed and applied. However, to improve the efficacy of immunotherapy, biomarkers that can predict the effects are needed. It has been reported that various microRNAs (miRNAs) in peripheral blood may be useful as non-invasive biomarkers. In this study, miRNAs influencing the efficacy of vaccine treatment were screened for in a microarray analysis of 13 plasma samples that were obtained from patients prior to vaccine treatment. To validate the screening results, real-time RT-PCR was performed using 93 plasma samples obtained from patients prior to vaccine treatment. Four candidate miRNAs were selected according to the results of the comprehensive analysis of miRNA expression, which were ranked using the Fisher criterion and the absolute value of the log2 ratio in the screening analysis. The validation analysis showed that in the HLA-A*2402‑matched patient group (vaccine-treated group), patients with a high expression of plasma miR-6826 had a poorer prognosis than those with a low expression (P=0.048). In contrast, in the HLA-A*2402-unmatched patient group (control group), there was no difference between the patients with high or low plasma miR-6826 expression (P=0.168). Similar results were obtained in the analysis of miR-6875 (P=0.029 and P=0.754, respectively). Moreover, multivariate analysis of the Cox regression model indicated that the expression of miR-6826 was the most significant predictor for overall survival (P=0.003, hazard ratio, 3.670). In conclusion, plasma miR-6826 and miR-6875 may be predictive biomarkers for a poor response to vaccine treatment. Although further clarification is needed regarding the functions of miR-6826 and miR-6875 and their relationship to immune‑related molecules, plasma miR-6826 and miR-6875 may be useful negative biomarkers for predicting the efficacy of vaccine treatment.
View Figures
View References

Related Articles

Journal Cover

January-2017
Volume 37 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kijima T, Hazama S, Tsunedomi R, Tanaka H, Takenouchi H, Kanekiyo S, Inoue Y, Nakashima M, Iida M, Sakamoto K, Sakamoto K, et al: MicroRNA-6826 and -6875 in plasma are valuable non‑invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer. Oncol Rep 37: 23-30, 2017
APA
Kijima, T., Hazama, S., Tsunedomi, R., Tanaka, H., Takenouchi, H., Kanekiyo, S. ... Nagano, H. (2017). MicroRNA-6826 and -6875 in plasma are valuable non‑invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer. Oncology Reports, 37, 23-30. https://doi.org/10.3892/or.2016.5267
MLA
Kijima, T., Hazama, S., Tsunedomi, R., Tanaka, H., Takenouchi, H., Kanekiyo, S., Inoue, Y., Nakashima, M., Iida, M., Sakamoto, K., Suzuki, N., Takeda, S., Ueno, T., Yamamoto, S., Yoshino, S., Okuno, K., Nagano, H."MicroRNA-6826 and -6875 in plasma are valuable non‑invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer". Oncology Reports 37.1 (2017): 23-30.
Chicago
Kijima, T., Hazama, S., Tsunedomi, R., Tanaka, H., Takenouchi, H., Kanekiyo, S., Inoue, Y., Nakashima, M., Iida, M., Sakamoto, K., Suzuki, N., Takeda, S., Ueno, T., Yamamoto, S., Yoshino, S., Okuno, K., Nagano, H."MicroRNA-6826 and -6875 in plasma are valuable non‑invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer". Oncology Reports 37, no. 1 (2017): 23-30. https://doi.org/10.3892/or.2016.5267